Lower mortality is the most important benefit of surfactant therapy.  All surfactants are equivalent for that benefit.  But surfactants differ in other responses that make up the clinical course:  Infasurf’s greater potency gives the most rapid and biggest initial improvement in respiratory status when treating patients with RDS.

Infasurf’s high SP-B content prolongs the positive effects, enabling some patient to receive fewer doses.

Infasurf’s high SB-B content makes it more resistant to inhibition by the serum proteins which form the membranes of Hyaline Membrane Disease.

Infasurf’s formulation produces a dose that is large enough to achieve good distribution, small enough to be a  well  tolerated and in a suspension with the lowest viscosity.